Still, we recognize that we are not alone in advancing this methodology. Numerous pioneering companies have played a crucial role in making different versions of GPC accessible to trials and, ultimately, patients. We would like to acknowledge and honor these trailblazers who boldly submitted their trials to regulatory authorities during the early stages of GPC industrialization. As a testament to their dedication, we provide a subset of these regulatory submissions, along with direct links to the FDA official database.